Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Minerva Pediatrica|May 18, 2016
IgE anti-Haemophilus influenzae type b (Hib) antibodies detected in serum of Hib-vaccinated asthmatic and non-asthmatic pediatric patientsTamar A Smith-Norowitz, Tehila A Saadia, Natalie Banniettis, et al.
Vaccines|August 28, 2025
Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. Vaccines 2024, 12, 974Kristen Feemster, William P Hausdorff, Natalie Banniettis, et al.
Vaccines|September 28, 2024
Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine DevelopmentKristen Feemster, William P Hausdorff, Natalie Banniettis, et al.
Vaccines|February 26, 2025
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of AgeTosin Omole, Enrique Pelayo, Aaron S Weinberg, et al.
Vaccines|October 28, 2025
Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192Tosin Omole, Enrique Pelayo, Aaron S Weinberg, et al.
Vaccine|February 25, 2023
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)Thomas Benfield, Mika Rämet, Piero Valentini, et al.
Vaccine|September 23, 2022
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, et al.
The Pediatric Infectious Disease Journal|August 11, 2023
Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three StudiesTimothy J Chapman, Shrita M Patel, Sheryl A Flores, et al.
Vaccine|December 15, 2022
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)Androniki Bili, Scott Dobson, Jeffrey Quinones, et al.
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Pageof 4